Cellectis: Monthly Information on Share Capital and Company Voting Rights

(Article 223-16 of General Regulation of the French financial markets authority)

Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS):

Listing market: NYSE Euronext Paris

ISIN code: FR0010425595

Date

Total number of sharesin the capital

Total number of voting rights 09/30/2017 35,415,473 40,693,242

About CellectisCellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 17 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells.Using its life-science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.comTalking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.

Disclaimer

This press release contains “forward-looking” statements that are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Further information on the risks factors that may affect company business and financial performance, is included in filings Cellectis makes with the Security Exchange Commission from time to time and its financial reports. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171004005967/en/

CellectisMedia:Jennifer Moore, 917-580-1088VP of Communicationsmedia@cellectis.comorCaitlin Kasunich, 212-896-1241KCSA Strategic Communicationsckasunich@kcsa.comorIR:Simon Harnest, 646-385-9008VP of Corporate Strategy and Financesimon.harnest@cellectis.com

Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Mar 2024 to Apr 2024